EA201590111A1 - Моноклональное антитело человека против белка vp1 вируса jc - Google Patents

Моноклональное антитело человека против белка vp1 вируса jc

Info

Publication number
EA201590111A1
EA201590111A1 EA201590111A EA201590111A EA201590111A1 EA 201590111 A1 EA201590111 A1 EA 201590111A1 EA 201590111 A EA201590111 A EA 201590111A EA 201590111 A EA201590111 A EA 201590111A EA 201590111 A1 EA201590111 A1 EA 201590111A1
Authority
EA
Eurasian Patent Office
Prior art keywords
virus
human antibody
antibody against
monoclonal human
jcv
Prior art date
Application number
EA201590111A
Other languages
English (en)
Other versions
EA029346B1 (ru
Inventor
Роберто Буриони
Массимо Клементи
Original Assignee
Помона Ричерка С.Р.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Помона Ричерка С.Р.Л. filed Critical Помона Ричерка С.Р.Л.
Publication of EA201590111A1 publication Critical patent/EA201590111A1/ru
Publication of EA029346B1 publication Critical patent/EA029346B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к нейтрализующему моноклональному антителу человека, направленному против белка VP1 вируса JC, который представляет собой вирус, вызывающий прогрессирующую мультифокальную лейкоэнцефалопатию (PML), а также к его применению для терапевтического или профилактического лечения инфекции JCV или заболевания, связанного с инфекцией JCV, такого как прогрессирующая мультифокальная лейкоэнцефалопатия (PML), и его применению в диагностике инфекций JCV или заболеваний, связанных с инфекцией JCV.
EA201590111A 2012-06-27 2013-06-26 Моноклональное антитело человека против белка vp1 вируса jc EA029346B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000570A ITTO20120570A1 (it) 2012-06-27 2012-06-27 Anticorpo monoclonale diretto contro il virus jc
PCT/IB2013/055257 WO2014002035A2 (en) 2012-06-27 2013-06-26 A human monoclonal antibody against the vp1 protein of jc virus

Publications (2)

Publication Number Publication Date
EA201590111A1 true EA201590111A1 (ru) 2015-04-30
EA029346B1 EA029346B1 (ru) 2018-03-30

Family

ID=46690644

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590111A EA029346B1 (ru) 2012-06-27 2013-06-26 Моноклональное антитело человека против белка vp1 вируса jc

Country Status (12)

Country Link
US (1) US10011648B2 (ru)
EP (1) EP2867257B1 (ru)
JP (1) JP6320375B2 (ru)
KR (1) KR102085305B1 (ru)
CN (1) CN104520318B (ru)
BR (1) BR112014032682B1 (ru)
CA (1) CA2877598C (ru)
EA (1) EA029346B1 (ru)
ES (1) ES2673230T3 (ru)
IT (1) ITTO20120570A1 (ru)
MX (1) MX356745B (ru)
WO (1) WO2014002035A2 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20120570A1 (it) * 2012-06-27 2013-12-28 Pomona Ricerca Srl Anticorpo monoclonale diretto contro il virus jc
CA2896824A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
JP2018203632A (ja) * 2017-05-30 2018-12-27 公益財団法人ヒューマンサイエンス振興財団 モノクローナル抗体及び測定キット
CN111417651B (zh) * 2017-12-01 2023-09-29 诺华股份有限公司 多瘤病毒中和抗体
EP3986930A4 (en) * 2019-06-19 2023-04-12 Icahn School of Medicine at Mount Sinai MONOCLONAL ANTIBODIES TO JC VIRUS
CN111732654B (zh) * 2020-06-19 2021-05-25 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的单克隆抗体1E10
CN118047865A (zh) * 2024-04-15 2024-05-17 北京市农林科学院 一种牛早幼粒细胞白血病蛋白单克隆抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3767755B2 (ja) * 1995-06-23 2006-04-19 エーザイ株式会社 抗ｊｃウイルス抗体
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
JP4840792B2 (ja) * 2001-11-22 2011-12-21 独立行政法人科学技術振興機構 ＪＣウイルスａｇｎｏを対象としたＰＭＬの治療
ES2731757T3 (es) * 2012-03-20 2019-11-18 Biogen Ma Inc Anticuerpos neutralizantes de JCV
ES2706173T3 (es) * 2012-03-20 2019-03-27 Biogen Ma Inc Anticuerpos de neutralización de JCV
ITTO20120570A1 (it) * 2012-06-27 2013-12-28 Pomona Ricerca Srl Anticorpo monoclonale diretto contro il virus jc
CA2896824A1 (en) * 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases

Also Published As

Publication number Publication date
WO2014002035A2 (en) 2014-01-03
US10011648B2 (en) 2018-07-03
BR112014032682B1 (pt) 2020-10-27
CN104520318B (zh) 2017-12-15
EP2867257B1 (en) 2018-03-14
JP6320375B2 (ja) 2018-05-09
BR112014032682A2 (pt) 2017-08-01
JP2015524389A (ja) 2015-08-24
CA2877598C (en) 2021-10-19
EP2867257A2 (en) 2015-05-06
EA029346B1 (ru) 2018-03-30
US20150191530A1 (en) 2015-07-09
CN104520318A (zh) 2015-04-15
KR102085305B1 (ko) 2020-03-05
ES2673230T3 (es) 2018-06-20
MX356745B (es) 2018-06-12
ITTO20120570A1 (it) 2013-12-28
MX2014015850A (es) 2015-08-20
WO2014002035A3 (en) 2014-02-27
KR20150023893A (ko) 2015-03-05
CA2877598A1 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
EA201590111A1 (ru) Моноклональное антитело человека против белка vp1 вируса jc
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
EA201300558A1 (ru) Соединения и способы для купирования боли
EA201400855A1 (ru) Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201591973A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201790413A1 (ru) Антитела против tigit
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201390874A1 (ru) Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
GEP20217263B (en) Anti-cd27 antibodies
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
EA201391616A1 (ru) Применение тиазолидных соединений для предотвращения и лечения вирусных заболеваний, рака и заболеваний, вызванных внутриклеточными инфекциями
EA201490288A1 (ru) Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
MX2018003282A (es) Anticuerpos neutralizantes de poliomavirus.
GT201200318A (es) Anticuerpos hacia gdf8 humano
EA201690212A8 (ru) Способы лечения или профилактики офтальмологических патологических состояний
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
EA201490588A1 (ru) Способы лечения вируса гепатита с
IN2014DN07149A (ru)
EA201170204A1 (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
EA201171237A1 (ru) Антитела к dkk-1

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM